The industry shaping 2021 agenda


The new infrastructure of Patient Centricity

10:00am – 11:00am (EST)

Panel:Embed the lived experience into your company’s DNA - change the hiring paradigm to achieve true patient centricity

  • See how embedding the patient, caregiver and HCP lived experience in your organization’s permanent workforce enables actionable patient-focused activities company-wide.
  • Move beyond traditional hiring criteria to prioritize lived experience over qualification and certification in certain patient advocacy roles and review committees - how and why
  • How embedding the HCP voice in pre-clinical provides vital understanding of HCP processes, patient subgroups, improved healthcare data utilization and commercial launch strategy.

Heather Dean VP, US Hematology Franchise Head Takeda

Wendy Erler Head of Patient Experience Alexion

Scott Townsend Operations Manager - GSK Response Center Alphanumeric

Heidi Floyd Patient Advocate and Consultant

Moderator: Gokul Gopalan VP, Global Medical Affairs Vertex

11:00am – 11:15am (EST)

Presentation:The new infrastructure of patient-centricity

  • Hear successful, top-down approaches for reshaping your company infrastructure, to be patient-centric to the core
  • Make the patient perspective a fully actionable resource that can be shared and tracked seamlessly cross-business
  • Learn the change management requirements at all levels, needed to make infrastructural evolution happen

Anthony Yanni SVP and Global Head Patient Centricity Astellas Pharma

11:15am – 11:30am (EST)

Presentation:Improve patient access through workflow optimization and digital innovation

  • Examine barriers to patient access that may contribute to financial toxicity, such as suboptimal workflow and tools, disparate systems, and inefficient fulfillment processes
  • Identify high-impact changes for reducing these barriers in order to improve access to intended therapy, shorten time to start on therapy, and maintain patients on therapy
  • Discover how Annexus Health can help optimize the delivery and fulfillment of your patient support programs to improve access to care

Joe Baffone Co-founder and CEO Annexus Health

11:30am – 11:45am (EST)

Presentation:Building new capabilities to embed patients' needs and perspectives

  • Build new capabilities to better understand the needs of patients in new therapy areas and to involve them in our work in meaningful ways
  • Learn how to embed input from patient-advocacy groups across the pharma value chain—from discovery research and clinical-trial protocols to health-outcomes research
  • Explore how focusing on the diverse impacts of chronic illness can enable creative ways to help patients holistically

Tina Deignan SVP and US Business Unit Head for Immunology Bristol Myers Squibb

11:45am – 12:00pm (EST)

Q&A:The new infrastructure of patient-centricity

Your opportunity to ask our expert speaker faculty questions

Anthony Yanni SVP and Global Head Patient Centricity Astellas Pharma

Tina Deignan SVP and US Business Unit Head for Immunology Bristol Myers Squibb

Joe Baffone Co-founder and CEO Annexus Health

Interactive learning

12:00pm – 1:00pm (EST)

Workshop:Listen to the data: How natural language processing can help you learn from different voices

  • Utilize natural language processing to gain vital insights from raw data such as social media, call center feeds, interviews with clinicians, and more
  • Use technology to get more value from secondary data and provide more cost effective alternatives to continuous data monitoring or primary research
  • Develop truly patient centric care with tailored approaches for large patient populations as well as sub-populations with differing needs

Hywel Evans Director, IQVIA NLP Insights Hub Linguamatics

1:00pm – 2:00pm (EST)

Break

Embed equity into clinical trial protocols and achieve inclusive patient journeys

2:00pm – 3:00pm (EST)

Panel:Overcoming site barriers in trial enrolment for underrepresented populations

  • Work smart with clinical trial sites to ensure data and intelligence shared for trial site selection reflects underrepresented patient communities proportionate to the diseased patient population
  • Understand the patient voice to learn about the patient burden of trial participation and provide flexible options to reduce the burden
  • Track and monitor trial enrolment in real-time and work with trail sites to remove operational barriers that may impede diverse enrolment
  • Develop a robust trial decentralization plan, and evolve hybrid and virtual trial design to enable better access to home testing kits, home visits, PROs and telemedicine for groups in less accessible locations
  • Embed a diverse range of patient voices in trial protocol design to understand inclusion determinants and eradicate barriers before they arise

Elizabeth George Clinical Trial Diversity Leader formerly GlaxoSmithKline

Dellann Elliott Mydland President & Chair EndBrainCancer Initiative

Marie-Ange Noué PhD Senior Director, Head of Scientific Communications EMD Serono

Moderator: Maimah Karmo President and CEO Tigerlily Foundation

3:00pm – 3:15pm (EST)

Case study:Why no strings attached patient education and engagement is essential for real progress in clinical trial enrolment diversity

  • Learn how a leading pharma company are reaching out to underrepresented patient communities with “no strings attached” awareness campaigns, to build greater trust and elevate the community discussion around clinical trials for industry
  • The need for a collective effort across industry to put business competitiveness aside to change the status-quo

Staci Hargraves Vice President, Patient and Portfolio Solutions Janssen

3:15pm – 3:30pm (EST)

Presentation:The growing role of clinical outcome assessments (COAs) in reducing burden and increasing regulatory success

  • Understand the growing importance of COAs in drug development from R&D through to post-launch
  • Learn how implementing an effective COA measurement strategy can increase your regulatory success
  • Explore the regulatory landscape, including challenges and opportunities for flexibility across disease areas, to increase precision and minimize clinical trial burden

Ebony Dashiell-Aje, PhD Senior Director, Patient Engagement and Outcomes Research BioMarin

3:30pm – 3:45pm (EST)

Presentation:A new (but old) Standard of Care: Pharma’s role in making trials accessible

  • Ensure your Standard of Care offering is appropriate, sufficient and well informed against insurance options available to your patient populations, with inclusion and health equity at the forefront.
  • Develop a communications plan that is concise and easily digestible for your target patients, and work with community leaders, patient leaders and patient groups to ensure your Standard of Care offering is widely known."

Monique C. Gore-Massy Global Lupus Patient Advocate Lupus Foundation of America COVID-19 Global Rheum Alliance

Nancy Di Dia Chief Diversity & Inclusion Officer, Executive Director Boehringer Ingelheim

3:45pm – 4:00pm (EST)

Q&A:Embed equity into clinical trial protocols and achieve inclusive patient journeys

Your opportunity to ask our expert speaker faculty questions

Staci Hargraves Vice President, Patient and Portfolio Solutions Janssen

Monique C. Gore-Massy Global Lupus Patient Advocate Lupus Foundation of America COVID-19 Global Rheum Alliance

Nancy Di Dia Chief Diversity & Inclusion Officer, Executive Director Boehringer Ingelheim

Ebony Dashiell-Aje, PhD Senior Director, Patient Engagement and Outcomes Research BioMarin

Patient-centric through diversity

10:15am – 10:35am (EST)

Presentation:The FDA: Driving diversity in clinical data

  • Learn why and how the FDA is placing a greater focus on clinical trial data diversity when assessing drug approvals
  • Understand the industry expectations with the FDA guidance on Enhancing the Diversity of Clinical Trial Populations
  • Hear the FDA perspectives on what satisfactory trial data looks like
  • How patient listening sessions and patient committees are forming regulation around diversity and inclusion in clinical trial data
  • How the FDA can be a partner to enable easy access to epidemiology and disease information, while pushing inclusive clinical research

Rear Admiral Richardae Araojo Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE), Office of the Commissioner FDA

Robyn Bent Director, Patient Focused Drug Development FDA

10:35am – 10:50am (EST)

Fireside Chat:The importance of establishing trust in communities of color to drive diversity in healthcare

  • Explore why there is a historical lack of medical mistrust in Black and Brown communities
  • Understand what health equity is, how industry leaders can learn to make decisions through this lens and why it must be a priority
  • Hear about why improving clinical trial representation through a community-engaged holistic approach can help diversify the clinical research pipeline

Dr Lauren Powell VP, US Medical Health, Equity and Community Wellness Takeda

Jamila M. Porter, DrPH, MPH Senior Advisor for Program and Strategy de Beaumont Foundation

10:50am – 11:00am (EST)

Q&A:Patient-centric through diversity

Your opportunity to ask our expert speaker faculty questions

Rear Admiral Richardae Araojo Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE), Office of the Commissioner FDA

Robyn Bent Director, Patient Focused Drug Development FDA

Dr Lauren Powell VP, US Medical Health, Equity and Community Wellness Takeda

Use behavior analysis and real patient perspectives to provide genuine clinical value

11:00am – 11:15am (EST)

PresentationLeverage critical insights from patients and care partners in trial protocols to create more inclusive, patient-friendly studies

  • Accelerate the adoption of patient-facing digital technologies in trials by incorporating key considerations such as technology interruptions, data management and remote training for users
  • Optimize patient engagement during design and execution of clinical trials, and improve proactive caregiver engagement
  • Ensure resources are adapted for diverse patient populations’ needs

Samantha Reyes Patient Engagement Lead, Senior Manager Amgen

Pete Schaeffer Projects, Clinical Platforms and Sciences TPR Analytics Director GlaxoSmithKline

11:15am – 11:30am (EST)

PresentationThe future is here now: Collaborate with patients to co-create digital solutions

  • Case study: How AstraZeneca collaborate with patients through their internal Patient Partnership Program (PPP) to test and deliver digital solutions as we move into the digital revolution in healthcare
  • The Covid-19 pandemic has accelerated the growth in the digital health space and patient centricity is vital to make this transition seamless
  • Hear first-hand from a patient that recently participated in AstraZeneca research testing a digital device integration, and learn from the challenges faced and lessons learnt
  • See the importance of working in partnership with patients and sites to ensure digital solutions don’t present barriers to participation and worsen experience in our clinical trials

Sponsor this thought-leadership opportunity

John Linnell Patient Advocate COPD Foundation

William Dott PhD Patient Insights and Solutions Lead – Digital Health AstraZeneca

11:30am – 11:45am (EST)

PresentationCollaborate across healthcare to gain critical patient perspectives and deliver preferred solutions

  • Expand patient benefit early and throughout the lifecycle of development by engaging with patients early and identifying needs and perspectives that can improve health outcomes
  • Identify outcomes that are most meaningful for patients and partner with patients to generate evidence to quantify value
  • Collaborate with regulators and health ecosystems to implement solutions that most benefit patients and society, such as new clinical or quality measures and new tools or evidence to prevent and manage disease

Rebecca Vermuelen VP Patient & Society Strategy Product Development, Head of Healthcare and Patient Partnership Teams Roche

Tom Willgross, PhD PD Data Sciences, Site Head, Welwyn People & Product Leader Roche

11:45am – 12:00pm (EST)

Q&A: Use behavior analysis and real patient perspectives to provide genuine clinical value

Your opportunity to ask our expert speaker faculty questions

Samantha Reyes Patient Engagement Lead, Senior Manager Amgen

Rebecca Vermeulen

William Dott

John Linnell Patient Advocate COPD Foundation

Interactive learning

12:00pm – 1:00pm (EST)

Roundtable:Interactive Commercial roundtables

1:00pm – 2:00pm (EST)

Break

Addressing pharma’s “one foot in the grave” approach to digital patient engagement

2:00pm – 3:00pm (EST)

Panel:Get with the times: Engage a rising tide of next generation patient influencers and social media users

According to a recent survey by WEGO Health, when an influencer shares medical condition information from a pharma company, 9 out of 10 patients will ask their doctor about it.

  • Gain an understanding of patient influencer types such as rising-influencers, nano-influencers and micro-influencers, their various channel touchpoints with patient groups and how pharma can work with them most effectively.
  • Explore commonly talked about condition categories and specific conditions on social media, as well as the inherent intersectionality of topics in terms of patient influencer advocacy.
  • Address why a robust patient influencer strategy is critical now. The importance and worth of patient influencers have grown exponentially during the last year and pharma’s commercial teams must adapt and upskill to remain in touch with their core patient needs.

Gigi Robinson Creative GenZ Thought Leader & Patient Advocate (Chronic Illness & Mental Health)

Linette Roungchun Autoimmune and skin patient advocate and performer

Buddy C. Njere Global Director, Patient Empowerment Strategy & Innovation AstraZeneca

Emily Downward Executive Director, Consumer Strategy & Storytelling Health Union

3:00pm – 3:15pm (EST)

Presentation:Realize an inclusive, hybrid patient interaction model: A holistic look at what we’ve gained and what we’ve lost through the pandemic

  • Gain patient feedback on key benefit areas relating to virtual physician-patient engagements in 2020/21.
  • Consider the shift to virtual on patient populations that cannot obtain smartphones, laptops and other vital devices for accessing care, and pave the way for equity and inclusion in future patient engagement models.
  • Devise next actionable steps for developing a patient care model that gives patients disease-appropriate options relating to how they interact with pharma and physicians.

Dr Bryn Jones Global Lead, Patient Affairs ViiV Healthcare

3:15pm – 3:30pm (EST)

Presentation:Partner with patients to create meaningful digital interactions

  • Utilize a comprehensive, interoperable eco-system that connects and engages all stakeholders in care
  • Hear insights from diverse patients to understand their real-life stories, and incorporate learnings into your workstreams that are based on what patients value most
  • Deliver patient-centric user experiences to match patient expectations of progress or success, based on lived experience

Sarah Krüg Founder and Executive Director Health Collaboratory / Cancer 101

3:30pm – 3:45pm (EST)

Q&A:Addressing pharma’s “one foot in the grave” approach to digital patient engagement

Your opportunity to ask our expert speaker faculty questions

Dr Bryn Jones Global Lead, Patient Affairs ViiV Healthcare

Sarah Krüg Founder and Executive Director Health Collaboratory / Cancer 101

Patient-centric through diversity

10:15am – 11:00am (EST)

Panel:Diversity, inclusion and equity outside of clinical trial data: A vital step for patient-centric front-runners

  • Discuss the critical need for diversity in pharma’s patient committees, patient advocacy partnerships and lived experience representatives - particularly in disease areas where race, gender, age, location, and socioeconomic factors greatly impact the patient journey
  • Identify “Health Deserts” for your disease area and develop a thorough inclusion strategy for these locations. Work with patient leaders, community leaders and advocacy groups to engage, educate, listen to their needs and build trust
  • Mindfully embed the voice of patient diversity and inclusion within the organization by hiring and training patients to be a part of your workforce
  • Showcase a truly patient-first approach by working with patient advocacy groups that hold pharma, themselves and other advocacy groups accountable to diversity, inclusion and equity

Christoph Koenen EVP & Chief Medical Officer Otsuka

Dr Owen Garrick MD VP Clinical Trial Delivery CVS Health

Shirley Sylvester, MD, MPH Senior Medical Director for Women's Health, Johnson & Johnson Office of the Chief Medical Officer Johnson & Johnson

Moderator: Trellis Usher Patient Experience SME, DEI Strategist & Advocate Nova Health Labs

Interactive learning

11:00am – 12:00pm (EST)

Roundtable:Interactive Clinical roundtables

Networking

12:00pm – 1:00pm (EST)

Networking:Networking

Come together to make new connections, unpack the learnings of this year's Pharma & Patient USA event, and discuss the future of pharma's patient-centric work

1:00pm – 2:00pm (EST)

Break

Diversifying commercial’s place in the new patient-centric equation

2:00pm – 3:00pm (EST)

Panel:Diversifying clinical trials: commercial’s critical seat at the table, defined

  • Hear from commercial leaders involved in research, development and trial design on how having a seat at the table directly benefits their commercial success post-launch.
  • Discuss how a cross-functional approach to diversifying clinical trials has been proven to reduce the risk of FDA approval challenges, challenging post-marketing commitments and loss of revenue.
  • Develop long-term, ongoing meaningful relationships with patient leaders to shape effective, patient-first launch strategies that reach and truly benefit underrepresented patient communities.

Camille Hertzka VP, Head of Medical Affairs, US Oncology AstraZeneca

Mark Plinio Chief Commercial Officer Evelo Biosciences

Elizabeth George Clinical Trial Diversity Leader formerly GlaxoSmithKline

Moderator: Esther Schorr EVP Remedy Health Media

3:00pm – 3:15pm (EST)

Presentation:Patient Experience redefined: Integrating patients most pressing needs from Research to Post Approval Access

  • Case study: See how patient experience is shaping product development starting in discovery through to post approval patient access
  • Learn how a culture of empowered grassroots leadership, shaped a company’s vision and established the ‘intra’preneurship that now systematically integrates patients most pressing needs across the continuum and accelerates access to  transformative health care solutions

Victoria DiBasio Global Head, Patient Informed Development & Health Value Translation Sanofi

Vanina Laurent-Ledru VP and Head, Global Public Affairs Sanofi Genzyme

Eric Racine VP & US Country Head, Public Affairs & Patient Advocacy Sanofi

3:15pm – 3:30pm (EST)

Presentation:Work with patients to be a meaningful channel of lived experience through storytelling

  • Work closely with patients to embed real life stories in every piece of product or educative communication.
  • Create relatable marketing campaigns that resonate with what patients value most in a treatment and match their expectations of progress or success, based on lived experience.
  • Develop a diverse and close network/ patient coalition via patient leaders, advocacy groups and influencers to access a widely inclusive range of genuine patient anecdotes.
  • Demonstrate an appropriate approach to inclusive storytelling, based on disease specific patient diversity analysis.

Christiane Lander MD

3:30pm – 3:45pm (EST)

Q&A:Diversifying commercial’s place in the new patient-centric equation

Your opportunity to ask our expert speaker faculty questions

Victoria DiBasio Global Head, Patient Informed Development & Health Value Translation Sanofi

Ella Balasa Cystic Fibrosis Patient Advocate

Laurie Meyers Senior Director, Experience and Engagement Design Genentech